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Abstract 
In different types of myeloid leukemia, increased formation of reactive oxygen species (ROS) has 
been noted and associated with aspects of cell transformation including the promotion of leukemic 
cell proliferation and migration, as well as DNA-damage and accumulation of mutations.  Work 
reviewed in this article has shown the involvement of NADPH oxidase (NOX)-derived ROS 
downstream of oncogenic protein-tyrosine kinases in both processes, and the related pathways have 
been partially identified. FLT3-ITD, an important oncoprotein in a subset of AML, causes activation 
of AKT and subsequently stabilization of p22phox, a regulatory subunit for NOX1-4. This process is 
linked to ROS formation and DNA damage. Moreover, FLT3-ITD signaling through STAT5 
enhances expression of NOX4, ROS formation and inactivation of the protein-tyrosine phosphatase 
DEP-1/PTPRJ, a negative regulator of FLT3 signaling, by reversible oxidation of its catalytic cysteine 
residue. Genetic inactivation of NOX4 restored DEP-1 activity and attenuated cell transformation by 
FLT3-ITD in vitro and in vivo. Future work is required to further explore these mechanisms and their 
causal involvement in leukemic cell transformation, which may result in the identification of novel 
candidate targets for therapy.  
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Introduction 
The formation of reactive oxygen species (ROS) is essential for normal cell physiology, and has been 
covered in detail in many excellent recent reviews [1-4]. Only a few aspects, which lay the 
groundwork for discussing specific ROS functions in leukemic cells, shall be briefly reiterated here.  
One important type of ROS are superoxide anions (O2.-) as they are produced as side-products along 
the respiratory chain in mitochondria [5], by activity of NADPH oxidases 1-3, and 5 [4], or by 
different other cellular oxidases. Hydrogen peroxide (H2O2), considered a particular important 
signaling molecule [6], can be produced by NADPH oxidase 4 (NOX4) and the Dual oxidases 1 and 2 
(DUOX1, 2), or by conversion of superoxide anions through superoxide dismutases (SOD). Further 
reactive species such as the short-lived hydroxyl radical (OH.), lipid hydroperoxides, peroxynitrite 
(NO3-) or hypochloric acid (HOCl) arise by metabolic reactions engaging superoxide or H2O2 (Fig.1). 
Among the specific physiologic functions of ROS is the reversible modification of proteins in the 
course of signal transduction in many cell types. Some of these modifications may not occur by direct 
interaction with any of the listed ROS species, but instead be relayed through intermediate oxidation 
products [3]. The formation of ROS and their reaction products is limited in time and extent by 
efficient cellular “anti-oxidant” systems. For example, peroxiredoxins (PRDXs) and catalase rapidly 
decompose H2O2. Thioredoxins and glutathione peroxidases can revert oxidative modifications, e.g. 
of oxidized protein-thiols or of lipid hydroperoxides, respectively. These and further antioxidant 
systems require NADPH and GSH for their restoration. The expression of several antioxidant 
proteins/enzymes is under positive control of the transcription factor NRF2, whose protein level and 
thereby activity is promoted by modification of an upstream “oxidant sensor” designated KEAP1 
(Fig. 1). If ROS formation exceeds the capacity of the antioxidant mechanisms, cells are exposed to 
“oxidative stress”, leading to damage of cellular macromolecules, and potentially cell death.  
Different types of cancer cells appear to produce higher levels of ROS than their normal counterparts 
[7, 8]. For example, early reports described enhanced ROS production in RAS-transformed fibroblasts 
[9], a finding which has later been corroborated in human CD34-positive hematopoietic progenitor 
cells [10]. More recently, also enhanced antioxidant activities were noted in cancer cells, for example 
as consequence of RAS-mediated transformation [11]. Consistent with a contributing role of this 
mechanism to tumor formation or maintenance, mutations in components of the KEAP1-NRF2 axis 
were found in different tumor types, leading to constitutive NRF2 activation [12-14]. It is likely that 
enhanced antioxidant capacity in some tumor entities is required for enabling cell survival under 
conditions of enhanced ROS production. ROS formation plays also a role in the interaction of cancer 
cells with their microenvironment, such as the cancer stem cell niche, with inflammatory cells or in 
the context of tumor angiogenesis. Clearly, alterations in ROS metabolism in cancer are complex, 
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presumably specific for certain cancer entities, and relate to both alterations in ROS formation and 
antioxidant defense. 
 
Table 1 
ROS formation in myeloid neoplasms, underlying mechanisms and functional consequences 
Leukemia entity Observed alterations in 
ROS pathways 
Functional consequences References 
CML BCR-ABL drives ROS 
formation through 
PI3K/AKT and glucose 
metabolism 
General inhibition of 
phosphatase activity 
[15, 16] 
CML ROS formation through 
PI3K, mitochondria, and 
AKT  
Genomic instability, 
development of TKI 
resistant cell clones 
[17, 18] 
CML NOX inhibitors synergize 
with TKI in inhibiting 
leukemic cells 
NOX inhibition as potential 
therapeutic strategy 
[19] 
CML BCR-ABL driven ROS 
formation involves 
STAT5 
Acquisition of BCR-ABL 
mutations 
[20] 
Myeloid 
neoplasms 
ROS overproduction 
downstream of oncogenic 
tyrosine kinases 
Cell growth and migration [21] 
Myeloid 
neoplasm 
RAS transformation of  
normal CD34+ cells 
drives ROS formation 
through NOX2 
Promotion of survival and 
proliferation 
[10] 
AML FLT3-ITD mutation 
drives ROS formation 
DNA damage and misrepair [22, 23] 
AML ROS production 
downstream of FLT3-
ITD is mediated by 
p22phox 
STAT5 activation [24] 
AML Overproduction of NOX-
derived ROS 
ROS promoted 
proliferation in vitro 
[25] 
AML FLT3-ITD drives ROS 
through NOX activation 
DNA damage [26] 
AML FLT3-ITD drives ROS 
formation and PTP 
oxidation 
Cell proliferation, 
myeloproliferative disease 
[27, 28] 
AML Reduced expression of 
peroxiredoxin 2 (PRDX2)  
Increased ROS levels upon 
cytokine stimulation;  
low PRDX2 levels 
correlated with poor 
prognosis 
[29] 
 
A plethora of data has indicated alterations in ROS metabolism in leukemia, either linked to etiology, 
prognosis or therapy responses [30, 31]. Many studies have supported the idea that ROS formation 
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may indeed causally contribute to leukemia growth and malignancy. For example, primary AML 
patient cells have been shown to frequently produce high levels of superoxide, a phenomenon which 
could be causally related to AML cell proliferation [25].   Only relatively recently, however, insights 
into the molecular basis of ROS formation in the leukemic cells were obtained. Importantly, the 
activity of key oncoproteins in myeloid leukemia, comprising BCR-ABL, FMS-like tyrosine kinase 3 
with internal tandem duplications (FLT3-ITD), and Janus kinase 2 (JAKL2) V617F could be 
mechanistically connected to metabolic alterations leading to enhanced ROS formation (Table 1, 
Chapter 2). We will summarize here recent findings on these mechanisms, focusing on FLT3-ITD-
driven ROS production in AML and its consequences.  
 
Oncogenic kinases as drivers of ROS formation in myeloid leukemia 
More than 90% of chronic myelogenous leukemia (CML) cases develop from a chromosomal 
abnormality known as the Philadelphia chromosome, which result from a reciprocal translocation 
between chromosomes 9 and 22, generating the chimeric kinase BCR-ABL (reviewed in [32]). BCR-
ABL is known to activate down-stream pro-survival pathways, for example, PI3K/AKT, JAK/STAT 
and RAF/MEK/ERK, resulting in resistance to apoptosis and proliferation [33]. BCR-ABL expressing 
cells have been shown to generate increased levels of ROS compared to untransformed cells [16]. 
Various sources of ROS have been examined in CML including leakage from the mitochondrial 
electron transport chain and NADPH oxidase generated ROS, particularly NOX4. Naughton et al., 
demonstrated NOX4-generated ROS contributing significantly to total endogenous ROS upon BCR-
ABL induction [34]. Treatment of CML cells with the BCR-ABL inhibitors, Imatinib and Nilotinib 
showed a significant decrease in ROS, coinciding with a post-translational down-regulation of the 
small membrane-bound protein p22phox, a key component of the NOX complex [35]. Treatment of 
BCR-ABL expressing cells with panNOX inhibitors, DPI or VAS2870 resulted in a reduction in ROS 
levels. Inhibition of both the PI3K/AKT and RAF/MEK/ERK pathways in combination resulted in 
p22phox down-regulation. BCR-ABL induced NOX4-generated ROS are dependent on PI3K/AKT 
and RAF/MEK/ERK activation and GSK3β inhibition [36]. Mitochondrial ROS also appear to 
contribute to total ROS in CML cells.  
The JAK2 V617F mutation is a substitution of a valine for a phenylalanine at amino acid 617 of JAK2 
destabilizing the JH2 “pseudokinase” domain of JAK2. It results in loss of the auto-inhibitory 
function of this regulatory domain, and in turn constitutive tyrosine kinase activity [37]. The mutation 
is present in approximately 6% of myelodysplastic syndromes (MDS) and 50% of myeloproliferative 
neoplasms (MPNs) [38]. Signaling of the JAK2 V617F oncoprotein results in constitutive activation 
of downstream pro-survival signaling, including activation of STAT5, PI3K/AKT and 
RAF/MEK/ERK, and in turn the formation of ROS [39, 40]. The increase in ROS is concurrent with 
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elevated levels of DNA damage [40]. In neutrophils from JAK2 V617F positive patients, an increased 
phosphorylation of the NOX2 subunit p47phox on Ser345 has been observed, suggesting a contribution 
of NOX2 activation to elevated levels of ROS in MDS [41]. 
FLT3, encoding the class III receptor tyrosine kinase FLT3 is the most frequently mutated gene in 
AML (up to 35%) [42, 43]. The prevalent mutations (found in 20-25% of AML patients) encode 
internal tandem duplications of sequence in the FLT3 juxtamembrane or the first part of the kinase 
domain, giving rise to FLT3-ITD oncoproteins. Since the affected kinase regions have a negative 
regulatory function for kinase activity, FLT3-ITD mutations result in ligand independent constitutive 
activation of the FLT3 receptor both at the plasma membrane but also of the newly synthesized kinase 
at the endoplasmic reticulum [44, 45]. Occurrence of FLT3-ITD has been associated with a worse 
patient prognosis [46-48]. Constitutive activity of FLT3-ITD activates down-stream pro-survival 
signaling pathways including PI3K/AKT, STAT5 (whereby STAT5 activation is independent of JAK 
kinase activation [49]) and RAF/MEK/ERK, which are known to promote survival, proliferation and 
transformation [50-52]. Recent findings have identified that in order for PI3K/AKT and 
RAF/MEK/ERK pro-survival pathways to be activated they must be located down-stream of FLT3-
ITD at the plasma membrane and STAT5 is located down-stream of FLT3-ITD at the ER [45, 53]. 
FLT3-ITD expressing cell lines have been shown to produce increased levels of ROS, DNA oxidation 
and double strand breaks (dsbs) when compared to FLT3-WT expressing cell lines [22, 27]. NOX-
generated ROS appear to be a primary source of ROS in FLT3-ITD expressing AML cells. Cells 
harboring the FLT3-ITD mutant have been shown to produce increased levels of NOX2 and NOX4 
and their partner protein p22phox compared to wild type FLT3 cells [26, 28]. Also, stimulation of 
FLT3-WT expressing cells with FLT3 ligand resulted in an increase in p22phox expression and of 
endogenous H2O2 levels [26]. There was no significant difference in mitochondrial ROS observed in 
FLT3-ITD or FLT3-WT cells, and cyclooxygenase-driven ROS formation did not contribute to total 
endogenous H2O2 in FLT3-ITD expressing cells ([26] and J. Moloney, T. Cotter, unpublished data). 
The enhanced ROS formation in FLT3-ITD expressing AML cells serves a signaling function in that 
it promotes cell proliferation and migration, and thereby contributes to leukemic cell transformation 
[21, 27]. In addition, FLT3-ITD driven ROS formation has been associated with DNA damage and 
accumulation of mutations [22, 23, 26]. Both aspects will be discussed in the following parts.  
 
ROS mediated alteration of transforming signal transduction: role of PTP oxidation.  
Protein phosphorylation of tyrosine residues plays a fundamental role in diverse cellular functions 
such as proliferation, growth, metabolism and differentiation. Protein-tyrosine kinases (PTKs) 
mediated signal transduction is regulated by protein-tyrosine phosphatases (PTPs) and failure of 
regulation of either protein family can contribute to unfavorable diseases like cancer. The human PTP 
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superfamily consists of more than 100 members. Many of these enzymes are identified by the unique 
consensus signature motif HCX5R involved in the catalytic function. Despite of their sequence and 
structural similarity, PTPs show a wide range of substrate specificity [54, 55].  
In AML, several members of the PTP superfamily were found to be altered by genetic aberration, 
promoter methylation or gene overexpression.  PTPN11 (also known as SHP-2) positively regulates 
FL ligand mediated FLT3 receptor signaling [56] and not surprisingly, activating mutations 
(commonly found SHP-2 E76K mutant) were identified in AML [57, 58]. Phosphatase PTEN 
negatively regulates PI3K signaling downstream of FLT3 receptor and is also mutated, though rarely 
in AML [59]. Several recent findings claim a role for deregulated gene expression of dual specificity 
phosphatases such as PRL2, PRL3 and DUSP6 in AML cases with and without FLT3 mutation [60-
62]. Recently STS1 and STS2 (also known as UBASH3B and UBASH3A), which belong to a PTP 
subfamily with histidine-based catalysis [54], were identified to be directly regulating the FLT3 
receptor tyrosine phosphorylation in hematopoietic stem cells [63]. However, their potential role in 
regulating constitutively active FLT3-ITD phosphorylation or FLT3 signaling in AML is yet 
unknown. Other examples include the transmembrane PTP PTPRD (PTPδ), which is downregulated 
by promoter methylation and may be a tumor suppressor in pediatric AML [64], and CDC25, which is 
mutated in familial platelet disorder with predisposition to AML [65].  
PTPs can modulate signal transduction in many ways, both negatively and positively. For example, 
they prevent the non-specific activation of PTKs, e.g. by averting the ligand-independent activation of 
RTKs. In other contexts, PTPs can promote signaling by activation of SRC family kinases or of the 
RAS pathway [55].   PTP activity is regulated by several mechanisms [66] and one such regulatory 
process is the reversible oxidation of the catalytic cysteine by ROS. H2O2 is considered an important 
ROS species in the PTP oxidation process. Upon oxidation, the active-site thiol moiety (-SH) is 
converted to a sulfenyl moiety (-SOH), which further reacts to more stable reaction products in 
intramolecular reactions, like sulfenylamides or disulfides. The widely presumed role of H2O2 in PTP 
oxidation may in fact be indirect [3] and other oxidants, such as lipid peroxides, can also effectively 
oxidize PTPs [67, 68].  PTP oxidation is typically transient, and reduction back to the active state is 
accomplished by interaction with cellular antioxidants like GSH or thioredoxin [67]. Reversible PTP 
inactivation facilitates the efficient RTK signal transduction in the cells upon ligand/growth factor 
stimulation [1]. Emerging reports claim, however, that PTPs are also important targets of 
pathologically generated ROS and that in such circumstances ROS mediated PTP inactivation could 
contribute to diseases like cancer. In support that such processes play a role in leukemia, an early 
study showed that high ROS levels in BCR-ABL transformed cells were associated with low levels of 
overall PTP activity, and treatment with antioxidants reverted these effects [15]. As outlined above, 
apart from BCR-ABL, also other myeloid leukemia-specific PTK oncoproteins, JAK2 V617F and 
FLT3-ITD, cause constitutive formation of elevated levels of ROS and their possible consequences 
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for PTP deregulation deserve attention.  The transmembrane PTP PTPRJ (also known as DEP-1, and 
CD148) was previously identified as bona fide PTP negatively regulating FLT3 receptor signaling in 
myeloid cells [69]. DEP-1 regulates FL ligand-induced FLT3 receptor signaling by associating with 
[70] and dephosphorylating FLT3 directly, thereby attenuating the activation of FLT3. When the role 
of DEP-1 for regulation of the FLT3-ITD oncoprotein was analyzed, DEP-1 was discovered to be 
oxidized and partially inactivated due to high levels of sustained ROS generation leading to elevated 
FLT3 activity and promotion of downstream signaling pathways, including STAT5 and RAS/ ERK1/2 
activation, causally contributing to cellular transformation [27]. Investigating the relevant ROS 
sources it could recently be convincingly shown that NOX4 mRNA and protein expression are 
elevated in FLT3-ITD positive AML cells and that NOX4 expression is directly transcriptionally 
regulated by STAT5 [28]. The NOX4 promoter possesses STAT binding elements, and STAT5 was 
demonstrated by ChIP assays to bind to these elements in a FLT3-ITD dependent manner. General 
interference with ROS formation by different means, downregulation of NOX4 with RNAi, or 
treatments with potential small molecule NOX4 inhibitors caused a pronounced decrease in ROS 
levels, rescued DEP-1 PTP activity, and attenuated transforming FLT3-ITD-driven signaling and cell 
transformation in vitro and in vivo.  Double depletion of DEP-1 and NOX4 partially rescued the effect 
of NOX4 depletion on transformation in vitro, suggesting that DEP-1 reactivation is essential for the 
inhibitory effect of NOX4 depletion.  Interestingly, murine hematopoietic stem cells transduced with a 
combination of FLT3-ITD with other potent oncogenic drivers (Hoxa9/Meis1, or MLL-AF9) and with 
genetic inactivation or downregulation of Nox4, did not grow in absence of cytokines in vitro, and 
were impaired in their capacity to elicit a myeloproliferative disease in sublethally irradiated recipient 
mice in vivo, respectively [28]. These findings revealed an important role played by NOX4 dependent 
ROS formation for oxidation of DEP-1, a bonafide PTP of FLT3 as a transforming event in FLT3-
ITD harboring aggressive AMLs (Figure 2). It will be interesting to know whether NOX4 dependent 
oxidative inactivation of DEP-1 is a selective mechanism or reflects a more general attenuation of 
PTPs in FLT3-ITD cells. While NOX4 may indeed be of interest as a therapeutic target in FLT3-ITD 
subtype AMLs, there are still several other potential sources of ROS formation, whose investigation is 
warranted.  
 
ROS-mediated DNA damage and potential implications for leukemia biology 
Genomic instability has been suggested to be the main cause of genetic diversity in cancer 
[71, 72]. Also disease progression in leukemia is associated with the accumulation of multiple 
mutated genes, resulting in resistance to apoptosis, abnormal cell growth and a block in differentiation 
[43, 73]. To explain the multiple mutations, the leukemic cells must likely acquire some form of 
genetic instability. Increasing evidence has shown that an increase in ROS formation, which is 
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associated with an increased DNA damage, may be important in this context. Oxidative DNA damage 
can cause a wide range of DNA alterations such as base pair mutations, insertions and deletions [74]. 
DSBs are one of the most dangerous lesions resulting in translocations and deletions. Alternative 
mechanisms involved in the generation of genomic instability include unfaithful or insufficient repair 
of DNA damage [75]. There are two DNA repair systems responsible for DNA dsb repair: a precise 
homologous recombination and a less precise non-homologous end-joining (NHEJ). Increased activity 
of the unfaithful AEJ repair pathway and down-regulation of the faithful NHEJ pathway were found 
associated with FLT3-ITD and BCR-ABL oncogenic signaling [23, 76, 77]. For example, an earlier 
study revealed that inhibition of FLT3-ITD using PKC412 resulted in significant decrease in dsbs and 
non- homologous repair of DNA damage. On the other hand, PKC412 had no effect on dsbs or the 
DNA repair pathways in FLT3-WT expressing cells [78], showing the importance and involvement of 
FLT3-ITD oncogene in genomic instability. It was also shown that increased repair of FLT3-ITD 
stimulated DNA damage contributes to drug resistance, which coincides with the high relapse rate 
associated with FLT3-ITD expressing AML cases [78]. The BCR/ABL mutation in CML is involved 
in a cycle of genomic instability similar to the FLT3-ITD mutation. The oncogenic effects of 
BCR/ABL cause increased levels of ROS production leading to enhanced DNA damage and 
compromised DNA repair [79]. Not only levels of DNA damage are much higher in BCR/ABL 
transformed cells compared to non-transformed cells, also the rate of DNA repair by unfaithful end 
joining systems is much higher. Importantly, the resulting accumulation of DNA damage and genetic 
abnormalities contributes to resistance against drugs that are commonly used in the treatment of CML 
including Imatinib [80, 81]. 
As outlined above, FLT3-ITD expressing cells have been shown to generate increased levels 
of ROS. p22phox and p22phox dependent NOX isoforms, particularly NOX4, have been shown to be the 
primary source of ROS in FLT3-ITD expressing cells [24, 28]. Recently, further research has 
therefore been carried out to investigate the specific pathways leading to ROS formation and ROS-
mediated DNA damage and genomic instability in FLT3-ITD positive AML cells [26].  MV4-11 
cells, a human AML-derived cell line with endogenous FLT3-ITD, and 32D cells, a murine 
immortalized myelobast-like cell line stably transfected with FLT3-ITD or FLT3-WT expressing 
plasmids, were employed in these studies. Inhibition of FLT3-ITD, NOX and p22phox (by siRNA) in 
MV4-11 cells resulted in a significant decrease in nuclear H2O2 measured with Nuclear Peroxy 
Emerald 1 (NucPE1). NOX4 and p22phox were shown to co-localize in the nucleus, thus reinforcing 
that nuclear NOX activity may contribute to genomic instability in AML [26]. FLT3-ITD expressing 
32D cells exhibited a 100% increase in endogenous H2O2 compared to FLT-WT expressing cells as 
quantified by flow cytometry using the H2O2 specific probe Peroxy Orange 1 (PO1), and a 25% 
increase in nuclear H2O2. There was, however, no significant difference in mitochondrial generated 
ROS between FLT3-ITD- and FLT3-WT-expressing cells. FLT3-ITD mediated DNA damage was 
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characterized using two different readouts: Phosphorylated histone H2AX (γH2AX), one of the most 
widely used marker for detecting DNA dsbs [82], and 8-hydroxy-2’ deoxyguanosine (8-OHdG), the 
predominant form of ROS-induced DNA lesion, also widely used as a marker of oxidative stress [83]. 
MV4-11 cells showed a 50% increase in dsbs compared to the FLT3-WT expressing AML cell line 
HL-60. In 32D cells, similar results were obtained. There was a 75% increase in levels of dsbs in 32D 
cells with FLT3-ITD compared to 32D cells with FLT3-WT. Moreover, in FLT3-ITD expressing 32D 
cells 100% higher levels of the oxidative stress marker 8-OHdG were detectable as compared to 
FLT3-WT expressing cells [26].  Knockdown of p22phox and thereby inhibition of p22phox dependent 
NOXs in MV4-11 cells resulted in a 30% decrease in the number of dsbs and DNA oxidation. Thus, 
in FLT3-ITD expressing cells p22phox is necessary for NOX-generated ROS to oxidatively damage 
DNA.  Conversely, p22phox knockdown in FLT3-WT expressing cells showed no effect on 
endogenous H2O2 and no alterations in dsbs.  However, when 32D FLT3-WT expressing cells were 
stimulated with the FLT3 ligand FL, an increase in p22phox protein expression was observed, and 
concurrently a 40% increase in endogenous H2O2 and a 20% increase in nuclear H2O2. The increase in 
p22phox protein expression coincided with a 50% increase in the number of dsbs, demonstrating the 
DNA damaging capacity of also H2O2 produced downstream of ligand-stimulated FLT3-WT. The 
possible contribution of individual NOXs in FLT3-ITD expressing 32D cells to ROS formation and 
dsbs was investigated by siRNA experiments. NOX4 knockdown had the largest effect resulting in a 
30% decrease in endogenous H2O2 levels and dsbs. NOX2 knockdown resulted in a 20% decrease in 
endogenous H2O2 and a 30% decrease in dsbs. In contrast, NOX1 knockdown resulted only in a 
marginal decrease in both H2O2 and DNA damage. Taken together, these data identified a p22phox and 
NOX2/4 axis for ROS formation in FLT3-ITD expressing cells causing DNA damage and genetic 
instability [26] (Figure 3). 
Unfortunately, ROS-mediated damage in AML and CML has major implications in the 
treatment of leukemia. It is increasingly more difficult to treat leukemia due to the accumulation in 
genetic abnormalities leading to resistance to protein tyrosine kinases inhibitors, for example, 
PKC412 and imatinib and further progression of the malignancy (Fig. 3). 
 
Future directions 
Despite the significant advances in understanding mechanisms of ROS formation in myeloid 
leukemia, notably downstream of the AML oncoprotein FLT3-ITD as outlined above, there are 
obviously many open questions. For example, more work appears warranted with respect to the 
topology of NOX-mediated ROS formation in the leukemic cells. H2O2, which may directly oxidize 
targets such as PTP molecules, is a stable molecule but still short-lived in cells due to very efficient 
cellular antioxidants. Therefore close proximity of target and H2O2 source may be essential for 
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interaction [2]. While nuclear p22phox and NOX4 may be important for eliciting DNA damage [26], 
the topological relationships of NOX4 and DEP-1/PTPRJ remain to be assessed. It appears also likely 
that in FLT3-ITD transformed cells, in addition to DEP-1/PTPRJ, other signaling molecules may be 
modified by oxidation such as other PTPs, protein kinases, or transcriptional regulators thereby 
contributing to cell transformation. Generic methods to detect oxidative protein modifications [84] 
may be helpful in identifying these targets. More work will also be needed to further establish the 
putative causal role of ROS formation for the biology of myeloid leukemia. For example, mouse 
strains with constitutive or conditional deficiency of NOX enzymes and several regulators are 
available [85] and may be investigated in transplantation-based or transgenic leukemia models. These 
studies may help in establishing components in the pathways for ROS formation in cells of myeloid 
leukemia as candidate drug targets. Inhibition of AML-cell proliferation and attenuation of the 
development of a FLT3-ITD driven myeloproliferative disease in mice by compounds reported to 
inhibit NOX4 have been recent promising findings [28]. However, many currently available 
compounds for interference with ROS formation are not entirely specific or controversial with respect 
to their mechanism of action [86]. Given the importance of NOX mediated ROS formation not only in 
leukemia but many other pathological contexts, the improvement of compounds can be expected and 
their testing in leukemia models will be an exciting perspective.  
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Figure legends 
Figure 1. Reactive oxygen (ROS) species, their origins, and cellular systems involved in ROS 
metabolism. Major ROS sources are the mitochondria and NADPH oxidases, and several 
oxidases/peroxidases also contribute to ROS formation. Superoxide anions, hydrogen peroxide, lipid 
peroxides, hypochloride, and the hydroxyl radical can oxidize and thereby modify cellular 
macromolecules. This can serve essential signaling functions (“green” range), but also cause 
deleterious effects (“red” range) designated oxidative stress, potentially leading to cell death. Several 
enzyme systems can modify the formed ROS, have antioxidant activity for preventing damage and 
reverting macromolecule oxidations (right part). NADPH and GSH are required for efficient 
antioxidant responses. The KEAP-NRF2 system is a master regulator of genes for antioxidant 
response. 
 
Figure 2. Role of ROS formation in leukemic cell transformation by the oncoprotein FLT3-ITD. 
FMS-like tyrosine kinase 3 (FLT3) with internal tandem duplications (FLT3-ITD) causes elevated 
ROS levels in cells of Acute Myeloid Leukemia (AML). This involves activation of signal transducer 
and activator of transcription 5 (STAT5), which can directly bind to the promoter of NADPH oxidase 
4 (NOX4), leading to elevated transcription. Increased NOX4 levels cause elevated formation of 
ROS, which oxidize the catalytic cysteine of density enhanced phosphatase-1 (DEP-1; a 
transmembrane protein-tyrosine phosphatase, also designated PTPRJ or CD148). In contrast to its 
activity in normal cells, the oxidized and thereby (reversibly) inactivated DEP-1 can no longer 
dephosphorylate FLT3-ITD, enabling elevated signal transduction and promoting cell transformation. 
 
Figure 3. Oncoprotein-driven ROS formation in myeloid cells causes DNA damage.   FLT3-ITD 
but also ligand-activated FLT3 or the BCR-ABL oncoprotein can drive oxidative DNA damage 
through a signaling chain involving AKT activation, elevated expression of p22phox, and activation of 
p22phox-interacting NADPH oxidases. DNA damage, involving DNA oxidation and generation of 
double-strand breaks, contributes to genetic instability and the accumulation of mutations associated 
with aggressive phenotypes, drug resistance and relapse. 
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